A Network Enhancement Method to Identify Spurious Drug-Drug Interactions

被引:1
|
作者
Wang, Huan [1 ,2 ]
Cui, Ziwen [2 ]
Yang, Yinguang [2 ]
Wang, Baijing [2 ]
Zhu, Lida [2 ]
Zhang, Wen [1 ,2 ]
机构
[1] Huazhong Agr Univ, Key Lab Smart Farming Agr Anim, Engn Res Ctr Intelligent Technol Agr, Minist Educ,Hubei Engn Technol Res Ctr Agr Big Da, Wuhan 430070, Peoples R China
[2] Huazhong Agr Univ, Coll Informat, Wuhan 430070, Peoples R China
基金
中国国家自然科学基金;
关键词
Drug-drug interaction networks; feature representation; graph embedding; network enhancement; spurious link identification; drug-drug interaction; ENSEMBLE METHOD;
D O I
10.1109/TCBB.2024.3385796
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
As medical safety and drug regulation gain heightened attention, the detection of spurious drug-drug interactions (DDI) has become key in healthcare. Although current research using graph neural networks (GNNs) to predict DDI has shown impressive results, it often fails to account for false DDI in the constructed DDI networks. Such inaccuracies caused by data errors, false alarms, or incorrect drug details can skew the network's structure and hinder the accuracy of GNN-based predictions. To tackle this challenge, we propose ANSM, a network-enhancement method specifically designed to identify and attenuate spurious links between drugs for ensuring the accuracy of DDI networks. ANSM integrates three key components: the feature extractor, the network optimizer, and the discriminative classifier. The feature extractor captures local structural features from drug node pairs, while the network optimizer leverages network information to improve feature extraction and reduce the impact of spurious DDI links. The discriminative classifier then identifies potential spurious links. Experimental results demonstrate that ANSM outperforms state-of-the-art methods in identifying spurious DDI.
引用
收藏
页码:1335 / 1347
页数:13
相关论文
共 50 条
  • [21] Drug-drug interactions in urology
    Michel, M. C.
    Schaefers, R. F.
    de la Rosette, J. J. M. C. H.
    UROLOGE, 2009, 48 (03): : 264 - +
  • [22] Drug-drug interactions in the ICU
    S Ray
    M Bhattacharyya
    J Pramanik
    S Todi
    Critical Care, 13 (Suppl 1):
  • [23] COCAINE DRUG-DRUG INTERACTIONS
    SANDS, BF
    CIRAULO, DA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1992, 12 (01) : 49 - 55
  • [24] Drug-drug interactions - Reply
    DeVane, CL
    JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 (05) : 225 - 227
  • [25] Predicting drug-drug interactions
    Tucker, GT
    DRUG METABOLISM REVIEWS, 2005, 37 : 5 - 5
  • [26] DRUG-DRUG INTERACTIONS IN HOSPITAL
    MOK, H
    MULPETER, K
    OCONNOR, P
    FEELY, J
    IRISH MEDICAL JOURNAL, 1991, 84 (01) : 26 - 26
  • [27] Drug-drug interactions with antipsychotics
    Meyer, Jonathan
    CNS SPECTRUMS, 2007, 12 (12) : 6 - 9
  • [28] Dolutegravir drug-drug interactions
    Mondleki, E.
    Maartens, G.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2022, 112 (03): : 194 - 195
  • [29] Pharmacodynamic Drug-Drug Interactions
    Niu, Jin
    Straubinger, Robert M.
    Mager, Donald E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1395 - 1406
  • [30] Drug-drug interactions with raltegravir
    Burger D.M.
    European Journal of Medical Research, 14 (Suppl 3) : 17 - 21